DCAT Value Chain Insights’ Production to Prescription cover art

DCAT Value Chain Insights’ Production to Prescription

DCAT Value Chain Insights’ Production to Prescription

By: DCAT
Listen for free

DCAT Value Chain Insights' Production to Prescription podcast, presented by the Drug, Chemical & Associated Technologies Association (DCAT), features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.

© 2026 DCAT Value Chain Insights’ Production to Prescription Economics Science
Episodes
  • Beyond ADCs: The Market for Next-Generation Conjugates

    Beyond ADCs: The Market for Next-Generation Conjugates
    Sep 3 2026

    Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative antibody drug conjugates (ADCs), which are still slated for strong growth.

    Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market analysis of these next-generation complex conjugates and ADCS.

    Support the show
    Show More Show Less
    18 mins
  • New Excipient Products: Are They Coming?

    New Excipient Products: Are They Coming?
    Aug 13 2026

    Support the show
    Show More Show Less
    32 mins
  • Pipeline Potential: Small-Molecule Drugs

    Pipeline Potential: Small-Molecule Drugs
    Jul 9 2026

    New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have been several large deals among the bio/pharma majors and smaller innovator companies, with one drug candidate recently gaining FDA approval. What is the market potential and both the promise and limitations of these drug classes? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest insights.

    Support the show
    Show More Show Less
    20 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet